Hillsdale Investment Management Inc. Has $5.55 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Hillsdale Investment Management Inc. lowered its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 4.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 323,700 shares of the biotechnology company's stock after selling 13,650 shares during the period. Hillsdale Investment Management Inc. owned about 0.14% of ADMA Biologics worth $5,551,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter worth $31,000. GAMMA Investing LLC lifted its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI acquired a new stake in ADMA Biologics during the 3rd quarter worth about $35,000. Vision Financial Markets LLC purchased a new position in ADMA Biologics during the 4th quarter valued at about $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at about $62,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Down 0.7 %

NASDAQ ADMA traded down $0.15 during trading on Tuesday, hitting $20.17. 893,667 shares of the company traded hands, compared to its average volume of 3,363,541. ADMA Biologics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.64. The business has a fifty day simple moving average of $16.84 and a 200 day simple moving average of $18.07. The company has a market capitalization of $4.77 billion, a P/E ratio of 72.16 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Remove Ads

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.